Data completeness
5/8 — Partial
SOAANZ (torsemide) by PharmaIN is clinical pharmacology mechanism of action micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of henle, where it inhibits the na/k/2ci-carrier system. Approved for heart failure. First approved in 2021.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOAANZ (torsemide) is an oral loop diuretic that inhibits the Na/K/2Cl-carrier system in the thick ascending portion of the loop of Henle. It is indicated for edema associated with congestive heart failure, renal disease, hepatic disease, and hypertension, either alone or in combination with other antihypertensive agents. The drug increases urinary excretion of sodium, chloride, and water without significantly altering glomerular filtration rate or acid-base balance.
$0.005BPart D
Peak7.4 years to LOESOAANZ is in peak commercial lifecycle with stable Part D spending ($5M in 2023, 10,270 claims), suggesting an established but modest revenue base with limited growth trajectory.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2CI-carrier system. Clinical pharmacology studies have confirmed this site of action in…
Worked on SOAANZ at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.